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Background: This retrospective cohort study aimed to determine if there are differences in cardiovascular co-morbidities,
blood pressure (BP) and continuous positive airway pressure (CPAP) use between patients with positional-dependent and
nonpositional-dependent obstructive sleep apnea (OSA).
Methods: Patients who were referred for overnight polysomnography for suspected OSA between 2007 and 2011
were screened. A total of 371 patients with OSA were included for analysis and divided into six groups according to
positional-dependency and severity of OSA: positional mild (n = 52), positional moderate (n = 29), positional severe
(n = 24), non-positional mild (n = 18), non-positional moderate (n = 70) and non-positional severe group (n = 178). The
six groups were compared for anthropometric and polysomnographic variables, presence of cardiovascular co-morbidities,
morning and evening BP and the changes between evening and morning BP, and CPAP device usage patterns.
Results: Demographic and anthropometric variables showed non-positional severe OSA had poor sleep quality and higher
morning blood pressures. Positional mild OSA had the lowest cardiovascular co-morbidities. Overall CPAP acceptance was
45.6%. Mild OSA patients had the lowest CPAP acceptance rate (10%), followed by moderate group (37.37%) and severe
group (61.88%, P< 0.001). However, the significant difference in CPAP acceptance across OSA severity disappeared when
the data was stratified by positional dependency.
Conclusions: This study found that positional mild OSA had less cardiovascular co-morbidities compared with subjects with
positional severe OSA. Independent of posture, CPAP acceptance in patients with mild OSA was low, but CPAP compliance
was similar in CPAP acceptors regardless of posture dependency of OSA. Since there are increasing evidences of greater
cardiovascular risk for untreated mild OSA, improving CPAP acceptance among mild OSA patients may be clinically
important regardless of posture dependency.
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Severe obstructive sleep apnea (OSA) is associated with an
increased risk of cardiovascular (CV) disease, including cor-
onary artery disease, heart failure, and stroke [1]. Although
often overlooked, mild OSA has been associated with a
higher prevalence of CV disease and significant CV co-* Correspondence: mimi3461@ms45.hinet.net
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reproduction in any medium, provided the ormorbidities, including hypertension and carotid artery ath-
erosclerosis [2-5]; although, other studies have not found
an association of OSA with hypertension and CV diseases
[6]. As the severity of mild OSA tends to worse over time,
active and effective treatment for mild OSA may be re-
quired [7].
The vast majority of patients with mild OSA exhibit
position-dependent apnea, in which the presence and se-
verity of symptoms are related to body position, and the
associated gravitational changes, during sleep [8,9]. Spe-
cifically, gravity pulls the jaw and the tongue downwardsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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the airway. Positional OSA is generally indicated by a
total apnea-hypopnea index (AHI) ≥ 5, with a > 50%
reduction in the AHI between the supine and lateral
positions, and an AHI that normalizes (AHI < 5) in the
lateral position [9].
Various treatment modalities are available for mild
OSA. Positional therapy, aimed at maintaining a non-
supine sleep position, is often used as first-line treat-
ment for patients with positional mild OSA, but has
only moderate efficacy and poor compliance [10]. Con-
tinuous positive airway pressure (CPAP) treatment sig-
nificantly reduces the AHI and improves sleep efficiency
in patients with OSA [11]; however both patients with
mild OSA and their clinicians are significantly less in-
clined to accept CPAP treatment [11]. Mandibular ad-
vancement devices, while generally preferred by patients
over CPAP, are not as effective in reducing sleep apnea
symptoms as CPAP [11]. In addition to its proven effi-
cacy for improving apnea symptoms, effective CPAP
treatment is associated with significantly decreased risks
for cardiovascular disorders, including reduced arterial
stiffness and decreased blood pressure (BP) in patients
with OSA [12-14].
Few studies have examined BP and CPAP use in pa-
tients with positional-dependent mild OSA. Therefore,
the primary aim of this study was to determine if there
are differences in BP (including morning BP, evening BP,
and the different in BP between evening and morning)
between patients who have positional and non-positional
mild OSA. We also evaluated patients with mild, moder-
ate, and severe OSA. CPAP usage patterns in these pa-
tients were also evaluated.
Methods
Study subjects
A total of 874 consecutive adult patients (aged ≥ 18 years)
were screened in this retrospective cohort study. All were
referred to the Chest and Sleep Clinic of Taipei Tzuchi
Hospital, the Buddhist Tzuchi Medical Foundation (New
Taipei City, Taiwan) for overnight polysomnography (PSG)
for suspected OSA between January 2007 and December
2011. None of the subjects were previously diagnosed with
OSA. Patients who underwent split-night sleep studies were
excluded (n = 46) due to the inherent difficulty in separat-
ing the diagnostic and therapeutic portions of the study for
postural effects [15]. Patients with PSG results that did not
include at least 15 minutes of data obtained in both supine
and non-supine positions were also excluded (n = 352) [15].
This time period was chosen with reference to a previous
study [15] and did not have to be consecutive. Patients with
PSG results indicating non-apnea (AHI < 5/h) were ex-
cluded (n = 103). We also excluded two patients whose
PSG data was missing. The remaining 371 patients withOSA (AHI ≥ 5) were included in the final analyses. These
371 patients were divided into six groups by positional-
dependency of OSA and the severity of OSA. Positional
OSA was defined as a > 50% reduction in the AHI between
the supine and lateral positions and an AHI that normal-
ized (AHI < 5) in a non-supine sleep position. This study
was approved by the Institutional Review Board of the
Taipei Tzuchi Hospital, the Buddhist Tzuchi Medical Foun-
dation. The informed patient consent was waived since this
was retrospective study.
Measurements
Anthropometric measurements and demographic data
Medical history and anthropometric data were recorded
prior to PSG study, and included body weight, height,
body mass index (BMI), neck, waist, and hip circumfer-
ence, waist-to-hip ratio, smoking status, hypertension,
anti-hypertensive agents usage, and presence of CV dis-
eases, defined as previous diagnosis of coronary artery
disease (CAD) or a history of cerebrovascular accident
(CVA).
Sleep parameters
Excessive daytime sleepiness was evaluated using the
Chinese version of the Epworth Sleepiness Scale (ESS)
before overnight PSG study [16]. An attended, standard
overnight PSG study was performed by trained sleep tech-
nicians at the sleep center. During PSG, electroencephal-
ography (EEG), electrooculography, chin and bilateral
anterior tibialis surface electromyography, electrocardiog-
raphy, airflow through the nose and mouth (registered
by thermistor), thoracoabdominal movements (registered
by respiratory inductive plethysmography), position (by
a sensor on the respiratory inductive plethysmography),
snoring, and oxygen saturation (by pulse oximetry) were
recorded. The PSG study lasted for at least 6 hours. PSG
data were analyzed by manual scoring for every 30-second
epoch by trained sleep technicians and were reviewed by
sleep specialists.
Sleep stage was scored by trained sleep technicians
using the standard criteria of Rechtschaffen and Kales
[17]. An apnea event was defined as an 80-100% reduction
in airflow lasting for at least 10 seconds. A hypopnea
event was defined as a reduction in airflow of at least 50%
for at least 10 seconds or at least a 30% reduction in air-
flow for at least 10 seconds as compared with baseline and
associated with at least 3% oxygen desaturation or with an
EEG arousal. AHI was calculated from the total number
of apnea and hypopnea events per hour of sleep. The
desaturation index (DI) was defined as > 3% oxygen desat-
uration per hour of sleep. The arousal index (AI) was
defined as arousal episodes per hour of sleep [18]. Sleep
efficiency was defined as the fraction of total sleep time to
total recording time. Sleep latency was defined as the time
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eye movement (REM) latency was defined as the time
from the first identifiable sleep stage to the first REM
sleep.
Blood pressure
BP was measured with the patient in the supine position by
trained technicians using an automated sphygmomanom-
eter (Welch Allyn Vital Signs Monitor 300 Series) with
an optimal cuff. The automated sphygmomanometer was
regularly calibrated at least every year by the technician
from the manufacturer who calibrated and/or validated the
instrument against manual measurement performed with
a standard mercury sphygmomanometer. Evening BP was
measured after 15 minutes of rest and before sleep onset.
Morning BP was measured immediately upon awakening
with the patient attached to all PSG equipments. Two con-
secutive determinations were made on each occasion, sepa-
rated by 5 minutes, and the results were averaged for both
the evening and morning BP readings. Mean arterial blood
pressure (MABP) was calculated using the systolic BP
(SBP) and diastolic BP (DBP): MABP = 1/3 SBP + 2/3 DBP.
Evening-to-morning BP difference was determined by:
morning BP – evening BP.
CPAP acceptance and compliance
All patients were offered treatment with CPAP. CPAP
acceptance refers to the proportions of patients who
meet the selection criteria for CPAP treatment and were
willing to try CPAP and actually to use it at home
[19,20]. CPAP compliance refers to the proportions of
patients using CPAP and delivering a pre-set level over
a given time period [19,20] Patients were routinely
followed up every 3 months at the outpatient clinic. Ac-
cording to the policy of our sleep center, we routinely
collected objective CPAP usage data (recorded by the
device software) at each visit. The CPAP usage included
percentage of days used, percentage of nights during
which CPAP was used for ≥ 4 hours, and the overall
mean hours used per night.
High CPAP compliance was defined as ≥ 4 hours of
CPAP per night for ≥ 70% of the nights [21]. Patients who
did not meet these levels of CPAP usage were defined as
having low CPAP compliance.
Statistical analysis
Results for continuous variables are presented as mean ±
standard deviation, whereas results for categorical variables
are presented as number (percentage). A Kolmogorov-
Smirnov test was used to test for normality. Baseline char-
acteristics between the positional OSA and non-positional
OSA groups were compared by one-way analysis of
variance (ANOVA) (continuous variables) or chi-square/
Fisher’s exact test (categorical variables). When significantresults were revealed by ANOVA, post-hoc tests with Bon-
ferroni correction or Dunnett’s test were then carried out.
Daytime sleepiness measurements, overnight polysomno-
graphy and blood pressure results among groups adjusting
for baseline differences were estimated by linear regression
models. All statistical assessments were evaluated at a two-
sided alpha level of 0.05 using SAS software, version 9.2
(SAS Institute, Inc., Cary, NC, USA).
Results
Baseline characteristics and anthropometric
measurements
The screening results are summarized in Figure 1. A total
of 874 adult patients met the inclusion criteria for screen-
ing. Of these, 46 were excluded for undergoing split-night
studies, 352 for not having sufficient data in both supine
and non-supine sleep positions, 103 for having normal
AHI, and 2 for missing PSG data.
The 371 patients who were included in the analysis
were divided into six groups: non-positional mild OSA
(group 1, n = 18), non-positional moderate OSA (group
2, n = 70), non-positional severe OSA (group 3, n = 178),
positional mild OSA (group 4, n = 52), positional mod-
erate OSA (group 5, n = 29), and positional severe OSA
(group 6, n = 24).
The baseline characteristics of these six groups are
summarized in Table 1. Except for age, CAD and CVA,
differences in gender, neck circumference, waist circum-
ference and hip circumference, ratio of waist to hip,
BMI, smoking history, CV co-morbidities, hypertension
and anti-hypertensive drug use among groups were
found. There were more males than females in the study
with the highest proportion of males having severe OSA
in both the non-positional and positional groups. Sub-
jects with severe OSA in the non-positional subgroup
had greater waist and hip circumference, higher waist-
to-hip ratio, and BMI than the subjects with severe OSA
than in the positional group. The neck circumference,
waist circumference, and hip circumference in subjects
with severe OSA (Group 3) in the non-position cohort
were larger compared with those with mild (Group 1) or
moderate (Group 2) OSA. There was no difference in
these same variables across disease severity in the pos-
itional cohort. A similar percentage of patients had
hypertension between the non-positional and positional
cohort of subjects.
Sleep parameters
Table 2 summarizes the daytime sleepiness measurements
and the overnight PSG results. ESS scores were not sig-
nificantly different across groups. After adjusting for gen-
der, waist-to-hip ratio, BMI, smoking and cardiovascular
co-morbidity, significant associations were found for AHI,
supine AHI, lateral AHI, DI, AI, S1, S2, REM, SaO2 mean,
Figure 1 Flowchart of patient enrollment. PSG: polysomnography; OSA: obstructive sleep apnea; AHI: apnea-hypopnea index.
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positional severe OSA had higher AHI (55.98 ± 1.01 epi-
sodes/hour), supine AHI (66.11 ± 1.16 episodes/hours),
lateral AHI (39.29 ± 1.35 episodes/hours) and lower SaO2
mean (90.65% ± 0.24%) than those with positional OSA.
Within the non-positional group, group 3 had the largest
values of the number of AHI, supine AHI, lateral AHI, DI,
AI, and S1, followed by group 2 than group 1 who were
similar in respect to the number of lateral AHI, DI, AI,
and S1. S2, SaO2 mean, and SaO2 minimal in group 3
were smaller than those in the other two subgroups. In
the positional group, the frequency of AHI and supine
AHI were different among three subgroups in order of
G6 >G5 >G4. The number of DI and AI in both group 4
and group 5 were smaller than those in the group 6. The
SaO2 minimal was significantly different only between the
group 4 and group 6.Blood pressure
As shown in Table 2, morning BP differed across all
groups (P = 0.002 for morning SBP, P =0.033 for morn-
ing DBP, P = 0.006 for morning MABP). BP was similar
between non-positional and positional group; however,
the morning DBP in the group 2 was lower compared
with group 3.CPAP acceptance and compliance
Table 3 shows CPAP acceptance and compliance. Mild
OSA patients showed the lowest CPAP acceptance rate
(10%), followed by moderate group (37.37%) and severe
group (61.88%, P < 0.001). However, the significant differ-
ence in CPAP acceptance across OSA severity disappeared
when the data was stratified by positional dependency.
The duration of follow-up varied across groups ranging
from 15.5 to 47 months.Discussion
This study found that positional mild OSA had less CV
co-morbidities and non-positional moderate group had
lower morning BP compared with severe OSA. In
addition, OSA showed varying associations with sleep pa-
rameters depending upon severity and positional depend-
ence. Patients with mild OSA had low CPAP acceptance
but similar CPAP compliance compared with patients
who had moderate or severe OSA. CPAP acceptance was
not dependent on posture dependency of OSA.
The prevalence of positional OSA in our study among
patients with mild OSA was 74.3% (52 of 70 mild OSA pa-
tients). This percentage is similar to that reported in a pre-
vious study using the same definitions for positional-
dependency [22]. Results of overnight PSG studies showed
Table 1 Baseline characteristics of patients with non-positional and positional obstructive sleep apnea
Non-positional Positional P-value
G1: Mild G2: Moderate G3: Severe G4: Mild G5: Moderate G6: Severe
(n = 18) (n = 70) (n = 178) (n = 52) (n = 29) (n = 24)
Age, years 61.39 ± 15.27 60.9 ± 13.06 56.39 ± 13.54 56.55 ± 13.2 54.76 ± 10.5 55.46 ± 13.95 0.999
Gender 0.011*
Female 6(33.33%) 25(35.71%) 34(19.1%)b 18(34.62%) 6(20.69%) 2(8.33%)a
Male 12(66.67%) 45(64.29%) 144(80.9%) 34(65.38%) 23(79.31%) 22(91.67%)
Neck circumference, cm 37.83 ± 3.63 38.22 ± 3.05 40.55 ± 3.7a,b 37.28 ± 3.05 38.66 ± 2.79 38.58 ± 2.62 <0.001*
Waist circumference, cm 92.64 ± 10.66 97.24 ± 9.08 103.21 ± 11.67a,b 91.99 ± 10.59 95.71 ± 8.34 92.64 ± 5.51c <0.001*
Hip circumference, cm 99.36 ± 9.95 103.43 ± 9.31 107.4 ± 10.55a,b 100.73 ± 7.5 102.71 ± 6.69 100.02 ± 4.99c <0.001*
Waist-to-hip ratio, % 0.93 ± 0.06 0.94 ± 0.05 0.96 ± 0.05 0.91 ± 0.07 0.93 ± 0.05 0.92 ± 0.05c <0.001*
BMI, kg/m2 26.27 ± 4.78 27.58 ± 4.76 29.98 ± 5.19 26.29 ± 3.41 27.74 ± 2.96 26.15 ± 2.78c <0.001*
Smoking history 0.017*
Past-smoker 4(22.22%) 14(20%) 42(23.6%) 9(17.31%) 6(20.69%) 11(45.83%)a
Never smoked 8(44.44%) 46(65.71%) 83(46.63%) 34(65.38%) 17(58.62%) 11(45.83%)
Current smoker 6(33.33%) 10(14.29%) 53(29.78%) 9(17.31%) 6(20.69%) 2(8.33%)
CV co-morbidities
Any CV co-morbidity 11(61.11%) 39(55.71%) 113(63.48%) 19(36.54%) 15(51.72%) 17(70.83%)a 0.018*
HTN 11(61.11%) 38(54.29%) 111(62.36%) 18(34.62%) 15(51.72%) 16(66.67%)a 0.015*
Anti-HTN drugs† 11(100%) 37(97.37%) 89(80.18%)b 18(100%) 13(86.67%) 14(87.5%) 0.021*
Dosage of anti-HTN drugs (number of tablets /day)† 2.23 ± 1.40 2.21 ± 1.15 1.98 ± 1.14 1.74 ± 1.24 1.35 ± 0.52 1.77 ± 0.92 0.192
CAD 0(0%) 3(4.29%) 13(7.3%) 0(0%) 1(3.45%) 2(8.33%) 0.394
CVA 2(11.11%) 15(21.43%) 32(17.98%) 4(7.69%) 6(20.69%) 5(20.83%) 0.307
BMI: body mass index; CV: cardiovascular; HTN: hypertension; CAD: coronary artery disease; CVA: cerebrovascular accident.
Results are mean ± standard deviation for continuous variables and number (percentage) for categorical variables.
Intergroup comparisons were made by analysis of variance followed by Bonferroni correction or Dunnett’s test for post-hoc test (continuous variables) or Chi-square / Fisher’s exact tests (categorical variables).
*Indicates a significant between group difference, P < 0.05.
†Only HTN patients were analyzed.
aIndicates significant difference from the mild subgroup within the nonpositional (or positional) group, p < 0.05.
bIndicates significant difference from the moderate subgroup within the nonpositional (or positional) group, p < 0.05.





















Table 2 Comparison of daytime sleepiness measurements, overnight polysomnography and blood pressure results for patients with non-positional and
positional obstructive sleep apnea
Non-positional Positional Adjusted
G1: Mild G2: Moderate G3: Severe G4: Mild G5: Moderate G6: Severe
(n = 18) (n = 70) (n = 178) (n = 52) (n = 29) (n = 24) P-value1
Daytime sleepiness measurements
ESS score 11.09 ± 1.31 9.91 ± 0.66 11.06 ± 0.43 9.65 ± 0.8 10.55 ± 1.02 10.24 ± 1.15 0.618
Overnight polysomnography
AHI, episodes/hour 12.68 ± 3.06 24.41 ± 1.55a 55.98 ± 1.01a,b 11.93 ± 1.86 21.97 ± 2.39a 44.41 ± 2.69a,b,c <0.001*
Supine AHI, episodes/hour 17.15 ± 3.54 33.98 ± 1.80a 66.11 ± 1.16a,b 18.55 ± 2.13 34.88 ± 2.76a 54.55 ± 3.1a,b,c <0.001*
Lateral AHI, episodes/hour 10.26 ± 4.13 14.35 ± 2.10 39.29 ± 1.35a,b 3.73 ± 2.48 2.25 ± 3.22c 5.17 ± 3.62c <0.001*
DI, episodes/hour 7.07 ± 3.38 15.12 ± 1.95 45.62 ± 1.27a,b 7.97 ± 2.33 14.90 ± 3.00 35.91 ± 3.37a,b <0.001*
AI, episodes/hour 30.87 ± 3.66 36.78 ± 1.86 56.65 ± 1.21a,b 19.50 ± 2.23 27.91 ± 2.86 46.99 ± 3.23a,b <0.001*
Sleep efficiency, % 68.83 ± 3.61 74.9 ± 1.84 77.62 ± 1.19 77.16 ± 2.2 78.46 ± 2.82 78.48 ± 3.18 0.224
Sleep latency, minute 28.85 ± 7.06 27.53 ± 3.59 22.3 ± 2.33 23.64 ± 4.3 16.58 ± 5.52 24.6 ± 6.22 0.601
REM latency, minute 120.2 ± 17.1 134.32 ± 8.83 141.17 ± 5.7 113.89 ± 10.29 126.42 ± 12.99 147.72 ± 15.25 0.238
S1, % 22.22 ± 3.18 24.01 ± 1.62 36.19 ± 1.05a,b 20.33 ± 1.94 23.30 ± 2.49 28.61 ± 2.8 <0.001*
S2, % 62.00 ± 3.16 60.83 ± 1.60 51.52 ± 1.04a,b 60.52 ± 1.92 59.14 ± 2.47 57.84 ± 2.78 <0.001*
S34, % 3.18 ± 1.35 2.72 ± 0.69 2.5 ± 0.44 4.01 ± 0.82 4.13 ± 1.06 2.61 ± 1.19 0.560
REM, % 12.60 ± 1.54 12.43 ± 0.78 9.78 ± 0.51 15.14 ± 0.94 13.43 ± 1.20 10.94 ± 1.35 <0.001*
SaO2 mean, % 92.92 ± 0.73 93.23 ± 0.37 90.65 ± 0.24
b 93.91 ± 0.45 94.14 ± 0.57 93.66 ± 0.65c <0.001*
SaO2 minimal, % 86.36 ± 1.90 81.22 ± 0.97
a 76.02 ± 0.63a,b 84.56 ± 1.17 81.87 ± 1.49 76.96 ± 1.67a <0.001*
Blood pressure
Evening SBP, mmHg 125.28 ± 3.43 127.46 ± 1.74 129.23 ± 1.13 124.02 ± 2.09 123.05 ± 2.68 126.01 ± 3.02 0.176
Evening DBP, mmHg 76.84 ± 2.49 77.15 ± 1.27 79.29 ± 0.82 76.47 ± 1.52 73.78 ± 1.95 78.76 ± 2.19 0.138
Evening MABP, mmHg 92.99 ± 2.61 93.92 ± 1.33 95.93 ± 0.86 92.32 ± 1.59 90.2 ± 2.04 94.51 ± 2.3 0.119
Morning SBP, mmHg 125.91 ± 3.27 126.83 ± 1.66 132.44 ± 1.08 125.06 ± 1.99 122.72 ± 2.56 126.56 ± 2.88 0.002*
Morning DBP, mmHg 78.37 ± 2.83 79.62 ± 1.44 83.74 ± 0.93b 79.06 ± 1.72 77.32 ± 2.21 80.81 ± 2.49 0.033*





















Table 2 Comparison of daytime sleepiness measurements, overnight polysomnography and blood pressure results for patients with non-positional and
positional obstructive sleep apnea (Continued)
Evening-to-morning SBP difference, mmHg 0.63 ± 2.67 −0.63 ± 1.36 3.21 ± 0.88 1.04 ± 1.63 −0.33 ± 2.09 0.54 ± 2.36 0.234
Evening-to-morning DBP difference, mmHg 1.53 ± 2.15 2.47 ± 1.09 4.45 ± 0.71 2.59 ± 1.31 3.54 ± 1.68 2.05 ± 1.89 0.526
Evening-to-morning MABP difference, mmHg 1.23 ± 2.11 1.43 ± 1.07 4.04 ± 0.7 2.07 ± 1.28 2.26 ± 1.65 1.55 ± 1.86 0.338
ESS: Epworth Sleepiness Scale; AHI: apnea-hypopnea index; DI: desaturation index; AI: arousal index; REM: rapid eye movement; SaO2: oxygen saturation; SBP: systolic blood pressure; DBP: diastolic blood pressure;
MABP: mean arterial blood pressure.
Results are estimated mean ± standard deviation.
*Indicates a significant association, P < 0.05.
1After adjusting for gender, ratio of waist to hip, BMI, smoking, and cardiovascular comorbidity, associations between factors and groups were assessed by linear regression and P-values were estimated using Wald’s
test. Post-hoc testes were examined by Boferroni correction.
aIndicates significant difference from the mild subgroup within the nonpositional (or positional) group, p < 0.05.
bIndicates significant difference from the moderate subgroup within the nonpositional (or positional) group, p < 0.05.





















Table 3 Continuous positive airway pressure acceptance and compliance among patients with non-positional and positional obstructive sleep apnea
Outcome Mild Moderate Severe P-value for comparison
among severity levelsNon-positional Positional Non-positional Positional Non-positional Positional
(n = 18) (n = 52) (n = 70) (n = 29) (n = 178) (n = 24)
CPAP acceptance by severity 7 (10.00%) 37 (37.37%) 125 (61.88%) <0.001*
CPAP acceptance in each group 1 (5.56%) 6 (11.54%) 26 (37.14%) 11 (37.93%) 110 (61.80%) 15 (62.50%)
CPAP compliance1 0.896
High 1 (100%) 4 (66.67%) 18 (69.23%) 7 (63.64%) 79 (71.81%) 11 (73.33%)
Low 0 (0%) 2 (33.33%) 8 (30.77%) 4 (36.36%) 31 (28.19%) 4 (26.67%)
Follow-up duration, months1 47.00 15.50 ± 9.57 20.62 ± 15.58 23.09 ± 19.54 22.27 ± 15.58 17.07 ± 14.68 NA
CPAP: continuous positive airway pressure, NA: not available due to only one case in one group.
Results are number (percentage) for categorical variables and mean ± standard deviation for continuous variables. Chi-square test or Fisher’s exact test was implemented for categorical variables.
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lower AI and better sleep efficiency than the patients with
mild OSA in the non-positional group, which also sup-
ports the results of a previous study [8]. AI was within
normal limits for our positional mild OSA group, but was
higher than normal in the non-positional mild OSA
group. Sleep efficiency was lower than normal in both
groups. While associations between OSA and hyperten-
sion have been generally accepted, studies have also
shown that sleep-disordered breathing, short sleep, and
poor sleep have been associated with hypertension in the
general population [23-25]. Therefore, patients experien-
cing poor sleep quality should receive optimal treatment
(including surgery or CPAP), regardless of OSA severity
or positional dependency in order to reduce the risk of de-
veloping hypertension.
The prevalence of hypertension in both mild OSA
groups (61.1% of non-positional mild OSA and 34.6% of
positional mild OSA patients) was similar to that re-
ported in a previous study [22] and was higher in both
groups than the prevalence in general population [26].
Much evidence supports elevated BP as a predictor of
CV disease. Both increased SBP and increased DBP have
been reported to be significant predictors of stroke and
coronary artery disease [27]. On average, SBP and DBP
readings in the morning are 10%-20% lower than BP
readings in the evening [28]. A recent study showed that
when this morning dip is replaced by a morning surge in
patients with hypertension, the risk of developing a
major CV event rises significantly [29]. Ting et al. re-
ported that elevated morning SBP was associated with
significantly greater respiratory disturbances, blood glu-
cose, and metabolic syndrome score [30]. Many patients
with OSA exhibit loss of the overnight dip in BP and ex-
hibit morning BP elevations, possibly due to sympathetic
nervous system over activity [31,32]. In this study, pa-
tients in both the positional and non-positional groups
showed a loss of evening to morning dip in BP, which
supports the aforementioned findings. Our finding sug-
gests that patients with positional mild OSA may have
the same level of risk of developing CV disease as pa-
tients with non-positional mild OSA. These results sug-
gest that there may be benefit in treating patients with
mild OSA regardless of positional dependency. Well-
designed randomized controlled trials are needed to dir-
ectly further address these issues.
Several studies have documented that poor sleep quality
is closely associated with hypertension [23-25]. There
was no evidence that improving sleep lowers blood pres-
sure, until recently. Huang et al. [33] found that the blood
pressure of poor sleepers was significantly reduced com-
pared to pretreatment values following zolpidem (a non-
benzodiazepine, non-hypotensive mild sedative with a
short elimination half-life of 2.5 hrs) treatment (P < 0.05)and more poor sleepers treated with zolpidem were con-
verted from nondipping hypertension to dipping hyper-
tension. Zolpidem treatment did not affect the blood
pressure of good sleepers. Additional randomized con-
trolled studies as necessary to further explore the potential
that improving sleep, possibly through the use of CPAP,
can reduce blood pressure.
Positional therapy is often relied upon as the primary
treatment modality for positional mild OSA. A variety of
strategies have been proposed for keeping patients in a
non-supine position, including the use of tennis balls, vi-
brating positional alarms, and wearable devices [34,35].
However, while positional therapy can moderately reduce
AHI in some patients, long-term compliance with pos-
itional therapy is poor as outlined in recent reviews
[10,36]. In addition, since CPAP clearly provides superior
improvement over positional therapy, positional therapy is
not recommended for first-line treatment of OSA [10].
The efficacy of CPAP in reducing apnea symptoms
and the risk of CV disorders has been clearly demon-
strated, making it the treatment of choice for patients
with OSA; however, patients are often reluctant to
accept CPAP treatment due to perceived inconvenience
and discomfort [37]. Unsurprisingly, few patients in our
study were willing to start CPAP treatment, especially in
the mild OSA patients (10%). However, the overall CPAP
acceptance of all the patients was 45.6%, and for patients
with mild OSA was 10%. The low acceptance rate may,
in part reflect the small sample size and the fact that in
Taiwan, the cost of CPAP is not covered by national or
commercial insurance and is paid out-of-pocket by the
patient and is 2–3 times higher than that in other coun-
tries [38]. Acceptance rates from other studies range
from 40-90% [38-45]. In the studies in which the accept-
ance rate is higher (about 70%), often CPAP is free to
subject participating in these trials [42-45]. Other rea-
sons that may have affected the acceptance rate are that
the retrospective study design is closer to the real-world
setting and that the strong national health insurance and
healthcare in Taiwan is so convenient and inexpensive
that the Taiwanese pay little attention on health main-
tenance. Overall CPAP compliance of our patients was
71.4% (120 out of 168 patients) and is comparable with
that found in studies in Europe and US which were
about 75% and 46%, respectively [42,43,46-49]. Reasons
for the wide range of compliance across countries in-
clude different definition of compliance and different
sources of CPAP. Moreover, free CPAP in prospective
studies results in higher compliance, while out-of-pocket
CPAP in retrospective studies results in lower com-
pliance. Nonetheless, the majority of our patients who
accepted CPAP treatment showed a high level of
compliance. Thus, educational support and physician in-
volvement to increase patient awareness of the increased
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of CPAP treatment for CV health might improve patient
acceptance and compliance [41].
There is growing evidence supporting the use of CPAP
in sleepy patients with mild OSA [50], however, the find-
ings are mixed and CPAP treatment of mild OSA is rec-
ommended as only a treatment option [51]. Given the
findings that there is an association of mild OSA with
hypertension and mild OSA tends to worse over time,
we suggest that CPAP treatment may benefit these pa-
tients. However, further randomized controlled studies
are required to better understand the potential benefit of
CPAP in treating mild OSA and hypertension.
This study is limited by the retrospective design and the
small number of patients included. Larger controlled stud-
ies are warranted to further study the effects of positional
dependency on BP, and CPAP efficacy and usage patterns
in patients with OSA. Besides, we used a thermistor (not
nasal pressure transducer to detect airflow and not an
esophageal pressure sensor to detect respiratory effort re-
lated arousal). These may result in an under-estimation of
the severity of OSA and consequently misclassification of
some patients in the mild and moderate OSA groups.
Conclusion
This study found that positional mild OSA had less cardio-
vascular co-morbidities and non-positional moderate OSA
had lower morning blood pressure compared with severe
group. CPAP acceptance by patients with mild OSA was
low, but CPAP compliance was similar to that of patients
with moderate or severe OSA. CPAP acceptance rate was
independent of posture dependency of OSA. Since there is
increasing evidences of greater cardiovascular risk for un-
treated mild OSA, optimal treatment (including CPAP or
surgery) for mild OSA regardless of posture dependency is
critical. Strategies to improving CPAP acceptance among
mild OSA patients will be the issue in the future.
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